Thank Patent Laws, Not Their Critics, for Generic GLP-1s
By David Kappos In late June, generic drug maker Teva Pharmaceuticals launched a generic version of Victoza, a blockbuster diabetes drug, in the United States. Victoza is one of the first GLP-1 drugs — the class of wildly popular diabetes and obesity treatments that includes Ozempic and Wegovy — to go off-patent. Within just a…
